3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Brand Engagement Network Inc. entered a settlement agreement with Evora Partners on September 30, 2026, to resolve about $1.3 million it owed under a January 2021 consulting agreement. Evora agreed to accept $825,000, including a $75,000 reimbursement of attorneys' fees, and will dismiss its pending lawsuit against the company. The deal resolves a liability already recorded in accounts payable and removes the pending litigation.
Settlement amount is $825,000, including a $75,000 reimbursement of Evora's attorneys' fees, against about $1.3 million owed.
The company has paid $175,000; the remaining $650,000 is due in installments through December 2026, guaranteed by BEN Capital Fund I, LLC.
Evora will dismiss its lawsuit filed September 2, 2026, in the U.S. District Court for the Southern District of New York.
Cyngn Inc. received a Nasdaq letter on October 14, 2026, saying its stock closed below $1.00 for 30 consecutive business days, so it no longer meets Nasdaq's minimum bid price requirement. The notice has no immediate effect on the listing, and the company has 180 calendar days, until April 12, 2027, to regain compliance. Shareholders face the risk of delisting if the company cannot regain compliance, and the company states there is no assurance it will do so.
Nasdaq notice dated October 14, 2026 cites closing bid price below $1.00 for 30 consecutive business days
Compliance deadline is April 12, 2027; compliance requires a closing bid of at least $1.00 for 10 consecutive business days
If not compliant by April 12, 2027, the company may be eligible for an additional 180 days, potentially requiring a reverse stock split
Company states there can be no assurance it will regain or maintain compliance
Mustang Bio said Nasdaq granted it an additional 180-calendar day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price rule after it missed the October 12, 2026 deadline. The company must close at or above $1.00 for at least 10 consecutive business days in that period, and it has said it may effect a reverse stock split if necessary. If it does not regain compliance, Nasdaq will issue a delisting notice, and the company says there is no assurance it will meet all continued listing requirements.
Nasdaq granted an additional 180-calendar day grace period, through April 12, 2027, letter dated October 13, 2026
Compliance requires a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally no more than 20
Company has stated it may effect a reverse stock split if necessary; failure to comply would lead to a delisting notice
Innovative Eyewear, Inc. (LUCY) received a Nasdaq notice on October 9, 2026, saying its common stock closed below $1.00 for 30 consecutive business days, so it is not meeting the minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company has until April 7, 2027 to regain compliance, and failure could lead to delisting proceedings.
Nasdaq notice dated October 9, 2026; stock closed below $1.00 for 30 consecutive business days
Company has 180 calendar days, until April 7, 2027, to regain compliance
Regaining compliance requires a closing bid of at least $1.00 for 10 consecutive business days
Company may seek a second 180-day period or request a Nasdaq Hearings Panel review; no assurance either will be granted
Quantum-Si received notice from Nasdaq on October 14, 2026 that it regained compliance with the $1.00 minimum bid price requirement as of October 13, 2026, closing a matter that began with a July 23, 2026 deficiency notice. The company said it will keep monitoring its closing bid price, and it warned that if it fails to maintain compliance, Nasdaq will likely issue another delisting notice.
July 23, 2026: Nasdaq notice after the closing bid price stayed below $1.00 for 30 consecutive business days
October 13, 2026: Company regained compliance with the Bid Price Requirement, per Nasdaq's October 14 notice
Nasdaq determined the closing bid price was at or above $1.00 for at least 10 consecutive business days
October 15, 2026: Company issued a press release on the compliance, filed as Exhibit 99.1
Aquestive Therapeutics said the FDA has accepted its resubmitted New Drug Application for Anaphylm as complete and classified it as a Class 2 response, with a PDUFA goal action date of March 16, 2027. The filing does not provide financial figures, and the outcome depends on the FDA's review, which the company says it expects to complete on or before the goal date.
FDA acknowledged the Anaphylm NDA resubmission as complete and classified it as a Class 2 response
PDUFA goal action date set for March 16, 2027
Aquestive submitted the resubmission on September 16, 2026, after a January 30, 2026 Complete Response Letter
Ex-U.S. submission to Health Canada remains on track for Q4 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.